JB
TGTX icon

Julian Baker’s TG Therapeutics TGTX Stock Holding History

Julian Baker’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,003,991
Closed -$15.5M – 136
2016
Q3 		$15.5M Hold
2,003,991
– – 0.14% 42
2016
Q2 		$12.1M Hold
2,003,991
– – 0.13% 49
2016
Q1 		$17.1M Hold
2,003,991
– – 0.18% 38
2015
Q4 		$23.9M Hold
2,003,991
– – 0.2% 36
2015
Q3 		$20.2M Hold
2,003,991
– – 0.19% 42
2015
Q2 		$33.2M Sell
2,003,991
-46,322
-2% -$733K 0.29% 35
2015
Q1 		$31.7M Hold
2,050,313
– – 0.26% 34
2014
Q4 		$32.5M Hold
2,050,313
– – 0.33% 31
2014
Q3 		$21.9M Sell
2,050,313
-110,652
-5% -$1.03M 0.28% 35
2014
Q2 		$20.3M Hold
2,160,965
– – 0.25% 37
2014
Q1 		$14.9M Sell
2,160,965
-38,691
-2% -$229K 0.19% 42
2013
Q4 		$8.58M Buy
2,199,656
+1,599,656
+267% +$6.46M 0.12% 50
2013
Q3 		$3.02M Buy
+600,000
New +$3.67M 0.04% 66

Other funds holding TGTX

BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Julian Baker's TGTX Position: Q4 2016 in Review

Julian Baker sold out of TG Therapeutics (TGTX) in Q4 2016, closing a stake of 2,003,991 shares — an estimated $15.5M sold.

Julian Baker first reported a position in TGTX in Q3 2013 and held it in 13 quarters. The position peaked at $33.2M in Q2 2015. 91 funds tracked by Wall St. Rank hold TGTX as of Q4 2016.

  • Julian Baker reported no remaining TG Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Julian Baker sold 2,003,991 TG Therapeutics shares in Q4 2016, an estimated $15.5M.
  • Julian Baker first reported a position in TG Therapeutics in Q3 2013 and held it in 13 quarters.
  • Julian Baker's TG Therapeutics position peaked at $33.2M in Q2 2015.
  • 91 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2016.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.